Investigational drug · Phase 2
Neflamapimod
Also called: VX-745
Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Nonfluent Variant Primary Progressive Aphasia (nfvPPA), Moderate to Severe Acute Ischaemic Stroke, Ischaemic Stroke.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 28, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
4
1 still active
All registered trials
8
Any phase or sponsor naming "Neflamapimod"
First trial start
2023
May 1, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Neflamapimod", any sponsor or status.
Conditions studied
As listed on its trial records.
- Nonfluent Variant Primary Progressive Aphasia (nfvPPA)
- Moderate to Severe Acute Ischaemic Stroke
- Ischaemic Stroke
- Dementia With Lewy Bodies
- Dementia With Lewy Bodies (DLB)
Approved drugs for the same conditions: Stroke prevention · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "Neflamapimod" as an intervention, largest first.
- Proof-of-Concept Study of a Selective p38 MAPK Alpha Inhibitor, Neflamapimod, in Subjects With Mild Alzheimer's DiseasePivotal-lookingCompleted
EIP Pharma IncIndustry
NCT03402659 · 161 participants · Start Dec 29, 2017 · Primary completion Jun 30, 2019
Drug: neflamapimod · For: Alzheimer Disease
Sites: Long Beach, California; San Diego, California; Santa Ana, California · 38 sites in all
- RewinD-LB - Clinical Study of Neflamapimod in Patients With Dementia With Lewy BodiesPivotal-lookingCompleted
EIP Pharma IncIndustry
NCT05869669 · 159 participants · Start May 1, 2023 · Primary completion May 29, 2025
Drug: Neflamapimod; Placebo · For: Dementia With Lewy Bodies
Sites: Phoenix, Arizona; Sun City, Arizona; Tucson, Arizona · 40 sites in all
- Cognitive Effects of Oral p38 Alpha Kinase Inhibitor Neflamapimod in Dementia With Lewy BodiesCompleted
EIP Pharma IncIndustry
NCT04001517 · 91 participants · Start Sep 30, 2019 · Primary completion Jun 30, 2020
Drug: Neflamapimod · For: Dementia With Lewy Bodies (DLB)
Sites: La Jolla, California; Santa Monica, California; Aurora, Colorado · 24 sites in all
EIP Pharma IncIndustry
NCT06987643 · 45 participants · Start Jun 20, 2025 · Primary completion Sep 23, 2026
Drug: Neflamapimod; Placebo · For: Moderate to Severe Acute Ischaemic Stroke; Ischaemic Stroke
Sites: Campbelltown, Australia; Liverpool, Australia; Birtinya, Australia · 10 sites in all
University Hospital, ToulouseAcademic, hospital or other
NCT03435861 · 34 participants · Start Oct 8, 2018 · Primary completion Apr 30, 2021
Drug: VX-745; placebo · For: Alzheimer Disease
Sites: Toulouse, France
EIP Pharma IncIndustry
NCT06815965 · 26 participants · Start Oct 16, 2024 · Primary completion Mar 11, 2026
Drug: neflamapimod · For: Dementia With Lewy Bodies (DLB)
Sites: Paris, France; Strasbourg, France
- Clinical Study of Neflamapimod in Patients With Primary Progressive AphasiaActive, not recruiting
EIP Pharma IncIndustry
NCT07033481 · 20 participants (planned) · Start Oct 2, 2025 · Primary completion Sep 2026
Drug: Neflamapimod; Placebo · For: Nonfluent Variant Primary Progressive Aphasia (nfvPPA)
Sites: Chicago, Illinois; Rochester, Minnesota; New York, New York · 7 sites in all
EIP Pharma IncIndustry
NCT03980938 · 15 participants · Start Jul 8, 2019 · Primary completion Oct 15, 2020
Drug: neflamapimod · For: Huntington Disease
Sites: Cambridge, United Kingdom
Newest research
PubMed records naming it or its code names, newest first.
- Uncoupling lens EMT: Blocking p38 MAPK suppresses TGF-β-driven myofibroblast transdifferentiation.
Wu Y, Flokis M, Soghomonian S, et al. · Exp Eye Res 2026
- Targeting Pro-Inflammatory Interleukin-1 Beta Signaling to Modulate Neuroinflammatory Processes Associated with Cognitive Decline in Dementia with Lewy Bodies.
Alam JJ, Germann UA, Maruff P · Cells 2026
- P38α deficiency alleviates myocardial ischemia/reperfusion injury by stabilizing cߛMyc to inhibit ferroptosis.
Ouyang X, Song S, Dong Y, et al. · Basic Res Cardiol 2026
- Nanotechnology-based encapsulation of neflamapimod: A new therapeutic strategy for lewy body dementia.
García-Simarro MP, Genicio N, Bañobre-López M, et al. · Colloids Surf B Biointerfaces 2026
- Bioinformatics and Machine-Learning Identification of Pulmonary Hypertension Biomarkers and Candidate Therapeutic Compounds.
Jiang C, Liang J, Jiang X · J Vis Exp 2026
- A Phase 2b randomized clinical trial of the oral p38α inhibitor neflamapimod in dementia with Lewy bodies (DLB).
Taylor JP, Alam JJ, Gomperts SN, et al. · Res Sq 2026
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.